Tests minocycline doses for retinitis pigmentosa, an inherited eye disease
Compares 100mg and 200mg minocycline with a placebo in adults with retinitis pigmentosa.
Plain-language title generated from the registry record
Registry title: A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07082855, who can take part
Where in China
- Zhongshan Ophthalmic Center,Sun Yat-Sen UniversityGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Trial code
- NCT07082855
- Record updated
- 24 July 2025
- Original description
This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety（100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.Read full original descriptionShow less
A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety（100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.
Inclusion: Age should be between 18 and 60 years old; Clinically diagnosed with retinitis pigmentosa, characterized by reduced electroretinogram (ERG) responses and constricted visual fields; In at least one eye, the amplitude of the 30Hz flicker ERG under photopic conditions should not be lower than 0 microvolts; The best-corrected visual acuity (BCVA, ETDRS) in both eyes should not be lower than 0.
Exclusion: Currently taking tetracycline antibiotics or any medications that may have adverse interactions with minocycline; Allergic to tetracycline antibiotics; History of ocular surgical intervention; History of uncontrolled severe comorbid conditions, such as renal disease, liver disease, autoimmune disease, thyroid dysfunction, psychiatric disorders, or idiopathic intracranial hypertension; Inability of the participant to comply with the study-required procedures, such as epilepsy, inability to fixate, or allergy to fluorescein. Inability to understand the content of the study, sign the informed consent form, or comply with the study procedures or follow-up visits; Presence of other ocular diseases, including glaucoma, uveitis, age-related macular degeneration, diabetic retinopathy, etc; Pregnant or breastfeeding; Syndromic retinitis pigmentosa; Currently participating in or having participated in another investigational study within the past 6 months; Inability to swallow capsules.